Characteristics of patients with MF/SS treated with alemtuzumab
Patient no. . | Age, y/sex . | Disease stage (events) . | No. of previous treatments . | Previous therapy . | No. of alemtuzumab doses/cumulative dose, mg . | Clinical response . |
|---|---|---|---|---|---|---|
| 1 | 42/M | IV A (MF) | 4 | 2 (TSEB, NM, fludarabine + prednisone, bexarotene†) | 7/223 | SD |
| 2 | 39/F | IV B (MF/SS) | 2 | 3 (ABVD/MOPP + XRT, pentostatin, C-MED) | 1/43 | PR |
| 3 | 74/M | II B (MF) | 2 | 2 (IFN + isotretinoin‡, C-MED) | 9/283 | PD |
| 4 | 61/F | II B (MF); immunoblastic transformation (LN) | 15 | IFN + isotretinoin + TSEB, pentostatin, hyper-CVAD, ESHAP, MINT × 2, TSEB, bexarotene, trimetrexate BCX, gemcitabine HCl§ ATRA, liposomal vincristine | 15/463 | SD |
| 5 | 67/F | IV A (MF/SS) | 10 | Steroids, cisplatin, PUVA, IFN + isotretinoin + C-MED + TSEB, pentostatin, bexarotene, IL-12, gemcitabine HCl, BCX, L-ATRA | 13/403 | PD |
| 6 | 68/M | IV A (MF/SS) | 7 | Photopheresis, IFN, TMTX, pentostatin, bexarotene, C-MED, ESHAP | 18/553 | PR |
| 7* | 56/F | IV B (MF/SS) | 4 | IFN-isotretinoin + C-MED + TSEB, bexarotene, PUVA, IFN | 1/30 | PD |
| 8* | 60/M | IV B (SS); angiocentric | 5 | PUVA, steroids/denileukin diftitox∥, SAHA, CHOP | 8/183 | PR |
Patient no. . | Age, y/sex . | Disease stage (events) . | No. of previous treatments . | Previous therapy . | No. of alemtuzumab doses/cumulative dose, mg . | Clinical response . |
|---|---|---|---|---|---|---|
| 1 | 42/M | IV A (MF) | 4 | 2 (TSEB, NM, fludarabine + prednisone, bexarotene†) | 7/223 | SD |
| 2 | 39/F | IV B (MF/SS) | 2 | 3 (ABVD/MOPP + XRT, pentostatin, C-MED) | 1/43 | PR |
| 3 | 74/M | II B (MF) | 2 | 2 (IFN + isotretinoin‡, C-MED) | 9/283 | PD |
| 4 | 61/F | II B (MF); immunoblastic transformation (LN) | 15 | IFN + isotretinoin + TSEB, pentostatin, hyper-CVAD, ESHAP, MINT × 2, TSEB, bexarotene, trimetrexate BCX, gemcitabine HCl§ ATRA, liposomal vincristine | 15/463 | SD |
| 5 | 67/F | IV A (MF/SS) | 10 | Steroids, cisplatin, PUVA, IFN + isotretinoin + C-MED + TSEB, pentostatin, bexarotene, IL-12, gemcitabine HCl, BCX, L-ATRA | 13/403 | PD |
| 6 | 68/M | IV A (MF/SS) | 7 | Photopheresis, IFN, TMTX, pentostatin, bexarotene, C-MED, ESHAP | 18/553 | PR |
| 7* | 56/F | IV B (MF/SS) | 4 | IFN-isotretinoin + C-MED + TSEB, bexarotene, PUVA, IFN | 1/30 | PD |
| 8* | 60/M | IV B (SS); angiocentric | 5 | PUVA, steroids/denileukin diftitox∥, SAHA, CHOP | 8/183 | PR |
M indicates male; F, female; SS, Sezary syndrome; MF, mycosis fungoides; LN, lymph node; TSEB, total skin electron beam; NM, nitrogen mustard; ABVD, doxorubicin (Adriamycin), bleomycin, vinblastine, DTIC; MOPP, mustard, vincristine, procarbazine, prednisone; C-MED, cyclophosphamide (Cytoxan), methotrexate, etoposide, dexamethasone; IFN, interferon; Hyper-CVAD, cyclophosphamide, vincristine, doxorubicin, dexamethasone; ESHAP, etoposide, methylprednisolone sodium succinate (Solu-Medrol), Ara-C, platinum; MINT, mesna, iphosphamide, mitoxantrone, paclitaxel (Taxol); IL-12, interleukin-12; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; SD, stable disease; PR, partial response; PD, progressive disease; XRT, radiation; ATRA, all transretinoic acid; L-ATRA, liposomal ATRA; PUVA, psoralen plus ultraviolet A; TMTX, trimetrexate; SAHA, suberoylanilide hydroxamic acid; and BCX, Biocryst.
Patient was treated off protocol. The other patients were enrolled in a phase 2 study of alemtuzumab.
Bexarotene.
Isotretinoin.
Gemcitabine HCl.
Denileukin diftitox.